How I treat juvenile idiopathic arthritis

A state of the art review

Rolando Cimaz, Achille Marino, Alberto Martini

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and an important cause of short and long-term disability. JIA encompasses several disease categories, each of which has distinct presentation, clinical manifestations, and, presumably, genetic background and etiopathogenesis. Correct choice and timely use of available medications to achieve early and sustained remission with as few side effects as possible remain challenges for the treating physician. This review aims to provide daily practical advice for the treatment of JIA patients on the basis of both our experience and existing recommendations.

Original languageEnglish
Pages (from-to)1008-1015
Number of pages8
JournalAutoimmunity Reviews
Volume16
Issue number10
DOIs
Publication statusPublished - Oct 2017

Fingerprint

Juvenile Arthritis
Rheumatic Diseases
Chronic Disease
Physicians
Therapeutics

Keywords

  • Journal Article
  • Review

Cite this

How I treat juvenile idiopathic arthritis : A state of the art review. / Cimaz, Rolando; Marino, Achille; Martini, Alberto.

In: Autoimmunity Reviews, Vol. 16, No. 10, 10.2017, p. 1008-1015.

Research output: Contribution to journalReview article

Cimaz, Rolando ; Marino, Achille ; Martini, Alberto. / How I treat juvenile idiopathic arthritis : A state of the art review. In: Autoimmunity Reviews. 2017 ; Vol. 16, No. 10. pp. 1008-1015.
@article{51f5514d4f40473298b846ecb1ee8e3e,
title = "How I treat juvenile idiopathic arthritis: A state of the art review",
abstract = "Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and an important cause of short and long-term disability. JIA encompasses several disease categories, each of which has distinct presentation, clinical manifestations, and, presumably, genetic background and etiopathogenesis. Correct choice and timely use of available medications to achieve early and sustained remission with as few side effects as possible remain challenges for the treating physician. This review aims to provide daily practical advice for the treatment of JIA patients on the basis of both our experience and existing recommendations.",
keywords = "Journal Article, Review",
author = "Rolando Cimaz and Achille Marino and Alberto Martini",
note = "Copyright {\circledC} 2017 Elsevier B.V. All rights reserved.",
year = "2017",
month = "10",
doi = "10.1016/j.autrev.2017.07.014",
language = "English",
volume = "16",
pages = "1008--1015",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - How I treat juvenile idiopathic arthritis

T2 - A state of the art review

AU - Cimaz, Rolando

AU - Marino, Achille

AU - Martini, Alberto

N1 - Copyright © 2017 Elsevier B.V. All rights reserved.

PY - 2017/10

Y1 - 2017/10

N2 - Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and an important cause of short and long-term disability. JIA encompasses several disease categories, each of which has distinct presentation, clinical manifestations, and, presumably, genetic background and etiopathogenesis. Correct choice and timely use of available medications to achieve early and sustained remission with as few side effects as possible remain challenges for the treating physician. This review aims to provide daily practical advice for the treatment of JIA patients on the basis of both our experience and existing recommendations.

AB - Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and an important cause of short and long-term disability. JIA encompasses several disease categories, each of which has distinct presentation, clinical manifestations, and, presumably, genetic background and etiopathogenesis. Correct choice and timely use of available medications to achieve early and sustained remission with as few side effects as possible remain challenges for the treating physician. This review aims to provide daily practical advice for the treatment of JIA patients on the basis of both our experience and existing recommendations.

KW - Journal Article

KW - Review

U2 - 10.1016/j.autrev.2017.07.014

DO - 10.1016/j.autrev.2017.07.014

M3 - Review article

VL - 16

SP - 1008

EP - 1015

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 10

ER -